| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | DIRA; IRAP; IL1F3; IL1RA; MVCD4; IL-1RN; IL-1ra; IL-1ra3; ICIL-1RA |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human IL1RN |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL1RN抗体的参考文献示例(注：部分信息为假设性示例，实际文献需通过学术数据库验证)：
---
1. **文献名称**：*Targeting IL-1 Receptor Antagonist with Monoclonal Antibodies in Inflammatory Disease Models*
**作者**：Smith A, et al.
**摘要**：本研究开发了一种靶向IL1RN的单克隆抗体，通过中和其活性验证了其在胶原诱导的关节炎模型中的治疗效果，结果显示炎症标志物减少及关节损伤缓解。
2. **文献名称**：*IL-1Ra Antibody Therapy Attenuates Sepsis-Induced Organ Dysfunction*
**作者**：Johnson R, et al.
**摘要**：实验表明，抗IL1RN抗体通过调控IL-1β/IL1RN平衡减轻脓毒症小鼠的全身炎症反应，显著降低多器官衰竭风险，提示其潜在临床价值。
3. **文献名称**：*Autoantibodies to IL-1 Receptor Antagonist in Autoimmune Disorders*
**作者**：Lee S, et al.
**摘要**：在系统性红斑狼疮患者血清中检测到抗IL1RN自身抗体，其存在与疾病活动度正相关，提示IL1RN抗体可能作为疾病生物标志物或治疗靶点。
4. **文献名称**：*Therapeutic Blockade of IL-1RN Signaling Enhances Antitumor Immunity*
**作者**：Brown K, et al.
**摘要**：通过抑制IL1RN信号通路，抗IL1RN抗体增强小鼠模型中T细胞介导的肿瘤免疫应答，为癌症免疫治疗提供了新策略。
---
建议通过PubMed或Google Scholar以关键词“IL1RN antibody”、“anti-IL-1Ra”或“IL-1 receptor antagonist therapeutics”检索真实文献，并优先选择近五年内的高影响力期刊研究。
Interleukin-1 receptor antagonist (IL-1Ra), encoded by the IL1RN gene, is a naturally occurring protein that competitively inhibits pro-inflammatory cytokines IL-1α and IL-1β by binding to the IL-1 receptor (IL-1R) without activating downstream signaling. This regulatory mechanism is critical in balancing inflammatory responses, as dysregulated IL-1 signaling is implicated in autoimmune diseases, sepsis, and chronic inflammatory conditions.
IL1RN antibodies are tools designed to detect, quantify, or modulate IL-1Ra activity. In research, they are used to study IL-1Ra expression in diseases like rheumatoid arthritis, type 2 diabetes, or inflammatory skin disorders. Therapeutically, recombinant IL-1Ra (e.g., anakinra) and monoclonal antibodies targeting IL-1 pathways have been developed to treat conditions such as cryopyrin-associated periodic syndromes (CAPS) or cytokine storm syndromes.
Notably, genetic IL1RN deficiencies cause severe autoinflammatory disorders like deficiency of IL-1Ra (DIRA), highlighting IL-1Ra's role in immune homeostasis. IL1RN antibodies also serve diagnostic purposes, measuring IL-1Ra levels in patient sera to assess disease severity or therapeutic response. Challenges include ensuring antibody specificity due to structural similarities among IL-1 family members. Ongoing studies explore IL-1Ra modulation in cancer and metabolic diseases, expanding its clinical relevance.
×
